Theresa Wingrove - Sep 15, 2023 Form 4 Insider Report for ImmunoGen, Inc. (IMGN)

Role
SVP OF REGULATORY AFFAIRS
Signature
/s/ Renee Lentini, Attorney-in-Fact
Stock symbol
IMGN
Transactions as of
Sep 15, 2023
Transactions value $
-$2,567,617
Form type
4
Date filed
9/19/2023, 05:27 PM
Previous filing
Jul 5, 2023
Next filing
Oct 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGN Common Stock Options Exercise $228K +50K +58.03% $4.55 136K Sep 15, 2023 Direct
transaction IMGN Common Stock Options Exercise $102K +33.3K +24.48% $3.05* 169K Sep 15, 2023 Direct
transaction IMGN Common Stock Options Exercise $67.9K +25.3K +14.95% $2.68* 195K Sep 15, 2023 Direct
transaction IMGN Common Stock Sale -$2.96M -192K -98.56% $15.44 2.81K Sep 15, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (right to buy) Options Exercise $0 -50K -17.14% $0.00 242K Sep 15, 2023 Common Stock 50K $4.55 Direct F2
transaction IMGN Stock Option (right to buy) Options Exercise $0 -33.3K -66.67% $0.00 16.7K Sep 15, 2023 Common Stock 33.3K $3.05 Direct F3
transaction IMGN Stock Option (right to buy) Options Exercise $0 -25.3K -66.67% $0.00 12.7K Sep 15, 2023 Common Stock 25.3K $2.68 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.30 to $15.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F2 On 2/7/2020, the reporting person was granted an option to purchase 333,450 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. As of the transaction date, 75% of the awarded options are vested.
F3 This option was granted on 7/18/2016 and is fully vested as of the transaction date.
F4 This option was granted on 9/30/2016 and is fully vested as of the transaction date.